Accessed 15 Jan 2022 Covid-19: Pfizers paxlovid is 89% effective in patients at risk of serious illness, company reports | The BMJ
However, in certain pathological processes of ischemiareperfusion injury, such as myocardial ischemia and stroke, this inhibition may exert a protective effect [75, 76]
If you experience any adverse effects following your injection, please contact your GP or call 111
W., Christiansen, J
Flags theoretical pathologic angiogenesis potential: PMC12446177 Evidence Summary Preclinical: IBD/colitis models: High remission rates, restored mucosal architecture, improved barrier function Tendon repair: Accelerated healing, improved tensile strength, reduced fibrosis Neurovascular: Sciatic nerve protection, enhanced blood vessel growth in nerve tissue Human data (emerging): Interstitial cystitis pilot (2024, n=12): 10/12 complete resolution, 2/12 at 80% improvement IV safety study (2025, n=2): no adverse effects on cardiac, hepatic, renal, or glucose biomarkers Knee pain retrospective (2021, n=17): 91.6% reported significant improvement No large-scale controlled trials published Safety: No immunosuppression or hormonal disruption in available data 2025 systematic review (HSS Journal): recommends caution due to limited high-quality clinical evidence 2025 narrative review: flags theoretical pathologic angiogenesis risk Stable in gastric acid (oral administration viable) No observed toxicity at therapeutic doses in published reports Foundational Reviews Sikiric P, Seiwerth S, et al
Valdivia, A., Ly, J., Gonzalez, L., Hussain, P., Saing, T., Islamoglu, H., Pearce, D., Ochoa, C., & Venketaraman, V
